Barclays’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-7,500
| Closed | -$1.32M | – | 5061 |
|
|
2025
Q4 | $1.32M | Hold |
7,500
| – | – | ﹤0.01% | 3246 |
|
|
2025
Q3 | $1.05M | Buy |
+7,500
| New | +$1.01M | ﹤0.01% | 3336 |
|
|
2025
Q2 | – | Sell |
-8,200
| Closed | -$1.12M | – | 5268 |
|
|
2025
Q1 | $1.12M | Sell |
8,200
-2,700
| -25% | -$386K | ﹤0.01% | 3036 |
|
|
2024
Q4 | $1.67M | Sell |
10,900
-11,800
| -52% | -$1.99M | ﹤0.01% | 3040 |
|
|
2024
Q3 | $4.4M | Buy |
22,700
+9,200
| +68% | +$1.92M | ﹤0.01% | 2201 |
|
|
2024
Q2 | $3.13M | Buy |
13,500
+10,800
| +400% | +$2.35M | ﹤0.01% | 1833 |
|
|
2024
Q1 | $582K | Sell |
2,700
-64,300
| -96% | -$15.1M | ﹤0.01% | 3494 |
|
|
2023
Q4 | $17.3M | Sell |
67,000
-63,400
| -49% | -$15.6M | 0.01% | 1128 |
|
|
2023
Q3 | $33.5M | Buy |
130,400
+106,200
| +439% | +$28.4M | 0.02% | 603 |
|
|
2023
Q2 | $6.89M | Sell |
24,200
-27,100
| -53% | -$8.07M | ﹤0.01% | 1163 |
|
|
2023
Q1 | $14.3M | Sell |
51,300
-135,500
| -73% | -$37.5M | 0.01% | 1003 |
|
|
2022
Q4 | $51.7M | Buy |
+186,800
| New | +$52.8M | 0.02% | 472 |
|
|
2022
Q3 | – | Sell |
-178,700
| Closed | -$36.4M | – | 4793 |
|
|
2022
Q2 | $36.4M | Buy |
+178,700
| New | +$36.5M | 0.02% | 491 |
|
|
2022
Q1 | – | Sell |
-57,000
| Closed | -$13.7M | – | 4967 |
|
|
2021
Q4 | $13.7M | Buy |
57,000
+56,900
| +56,900% | +$14.6M | 0.01% | 1102 |
|
|
2021
Q3 | $28K | Sell |
100
-25,000
| -100% | -$8.19M | ﹤0.01% | 4283 |
|
|
2021
Q2 | $8.69M | Buy |
25,100
+5,000
| +25% | +$1.51M | ﹤0.01% | 1265 |
|
|
2021
Q1 | $5.62M | Sell |
20,100
-99,400
| -83% | -$26.8M | ﹤0.01% | 1420 |
|
|
2020
Q4 | $29.3M | Buy |
119,500
+38,800
| +48% | +$10M | 0.02% | 662 |
|
|
2020
Q3 | $22.9M | Buy |
80,700
+56,100
| +228% | +$15.6M | 0.01% | 690 |
|
|
2020
Q2 | $6.58M | Sell |
24,600
-75,700
| -75% | -$22.8M | 0.01% | 1184 |
|
|
2020
Q1 | $31.7M | Sell |
100,300
-10,900
| -10% | -$3.31M | 0.03% | 459 |
|
|
2019
Q4 | $33M | Buy |
111,200
+20,700
| +23% | +$5.74M | 0.02% | 689 |
|
|
2019
Q3 | $21.1M | Sell |
90,500
-2,400
| -3% | -$559K | 0.01% | 857 |
|
|
2019
Q2 | $21.7M | Sell |
92,900
-13,900
| -13% | -$3.21M | 0.01% | 879 |
|
|
2019
Q1 | $25.2M | Buy |
106,800
+52,800
| +98% | +$16.6M | 0.02% | 726 |
|
|
2018
Q4 | $16.3M | Sell |
54,000
-39,400
| -42% | -$12.6M | 0.01% | 857 |
|
|
2018
Q3 | $33M | Buy |
93,400
+47,200
| +102% | +$16.3M | 0.02% | 600 |
|
|
2018
Q2 | $13.4M | Buy |
46,200
+14,700
| +47% | +$4.13M | 0.01% | 1034 |
|
|
2018
Q1 | $8.63M | Sell |
31,500
-94,700
| -75% | -$29.4M | 0.01% | 1265 |
|
|
2017
Q4 | $40.2M | Sell |
126,200
-40,100
| -24% | -$12.9M | 0.03% | 488 |
|
|
2017
Q3 | $52.1M | Buy |
166,300
+1,500
| +0.9% | +$444K | 0.05% | 284 |
|
|
2017
Q2 | $44.7M | Buy |
164,800
+116,400
| +240% | +$30.8M | 0.05% | 309 |
|
|
2017
Q1 | $13.2M | Sell |
48,400
-262,200
| -84% | -$74.1M | 0.01% | 728 |
|
|
2016
Q4 | $88.1M | Buy |
310,600
+236,300
| +318% | +$70M | 0.1% | 162 |
|
|
2016
Q3 | $23.3M | Sell |
74,300
-240,600
| -76% | -$71.3M | 0.03% | 487 |
|
|
2016
Q2 | $76.1M | Buy |
314,900
+241,900
| +331% | +$63.8M | 0.1% | 162 |
|
|
2016
Q1 | $19M | Sell |
73,000
-217,100
| -75% | -$57.3M | 0.03% | 490 |
|
|
2015
Q4 | $88.8M | Sell |
290,100
-137,300
| -32% | -$39.5M | 0.11% | 166 |
|
|
2015
Q3 | $124M | Buy |
427,400
+198,400
| +87% | +$65.5M | 0.15% | 109 |
|
|
2015
Q2 | $92.3M | Buy |
229,000
+95,800
| +72% | +$38.4M | 0.1% | 159 |
|
|
2015
Q1 | $56.2M | Buy |
133,200
+26,000
| +24% | +$10.2M | 0.06% | 286 |
|
|
2014
Q4 | $36.3M | Buy |
107,200
+3,500
| +3% | +$1.13M | 0.04% | 475 |
|
|
2014
Q3 | $34.2M | Buy |
103,700
+26,500
| +34% | +$8.74M | 0.03% | 471 |
|
|
2014
Q2 | $24.3M | Sell |
77,200
-127,300
| -62% | -$38.3M | 0.03% | 604 |
|
|
2014
Q1 | $62.4M | Sell |
204,500
-238,400
| -54% | -$75.7M | 0.07% | 241 |
|
|
2013
Q4 | $124M | Buy |
442,900
+195,600
| +79% | +$50.6M | 0.13% | 119 |
|
|
2013
Q3 | $59.4M | Sell |
247,300
-146,200
| -37% | -$32.7M | 0.07% | 240 |
|
|
2013
Q2 | $84.7M | Buy |
+393,500
| New | +$84.1M | 0.11% | 140 |
|
Other funds holding BIIB
VCM
VPM
Barclays's BIIB Position: Q1 2026 in Review
Barclays reduced its Biogen (BIIB) stake by 58% in Q1 2026, selling an estimated $139M and leaving 551,474 shares worth $101M. The position accounts for 0.02% of the portfolio, ranked #483.
Barclays first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $230M in Q4 2025. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Barclays held 551,474 shares of Biogen worth $101M as of Q1 2026.
- Barclays sold 753,533 Biogen shares in Q1 2026, an estimated $139M.
- Biogen made up 0.02% of Barclays's portfolio in Q1 2026, its #483 holding.
- Barclays first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- Barclays's Biogen position peaked at $230M in Q4 2025.
- 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.